IDH2 and acute myeloid leukemia: In a randomized Phase 2 study in newly diagnosed IDH2-mutated AML of azacitidine + enasidenib compared with enasidenib alone, the combination resulted in a significantly higher CR rate (53% versus 12%) and overall response rate (71% versus 42%), and a trend for improved EFS (17 months versus 11 months).